Anatomical-Clinical Base of Adenocarcinoma Pancreatic

Last updated: January 29, 2025
Sponsor: University Hospital, Toulouse
Overall Status: Active - Recruiting

Phase

N/A

Condition

Carcinoma

Neoplasms

Adenocarcinoma

Treatment

collection of biological samples

Clinical Study ID

NCT06128343
RC31/21/0191
2021-A01050-41
  • Ages 18-120
  • All Genders

Study Summary

BACAP-2 is a prospective biobank dedicated to the pancreatic adenocarcinoma including clinical data and biological samples from tumor. The aim is to enrich the previous propective collection BACAP in order to support future research projects.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient with pancreatic mass syndrome explored by ultrasound endoscopy withcytopuncture or

  • Patient with pancreatic mass syndrome explored by an abdominal scanner with andwithout injection of product contrast and/or puncture of the mass or secondarylesions by radiological route or

  • Patient with pancreatic adenocarcinoma proven histologically and/or cytologically

Exclusion

Exclusion Criteria:

  • Patient with a pancreatic tumor whose analysis histological is not an adenocarcinoma

  • Pregnant or breastfeeding patient

Study Design

Total Participants: 1500
Treatment Group(s): 1
Primary Treatment: collection of biological samples
Phase:
Study Start date:
November 16, 2023
Estimated Completion Date:
February 28, 2035

Study Description

Pancreatic cancer represents the fourth cause of death by cancer in Western countries. In over 90% of cases, it is due to an adenocarcinoma. The only curative treatment for pancreatic cancer remains the surgical exeresis. This one can only be suggested as a curative treatment in only 10 to 15% of cases. Besides, prevention or screening is difficult to set up due to the absence of clearly identified risk factors or groups and to the absence of useful markers for the diagnosis in clinical practice.

The research efforts in this area must face a double challenge: saving time while improving the diagnosis period and strengthen the therapeutic equipment. It is important to identify and characterise the new molecular markers applicable for a better diagnosis and/or treatment (especially the response factors to chemotherapy).

The present project aims to enrich with fresh tumor tissue and somatic genetic analysis the existing propective collection BACAP in order to support support future research projects on:

  • the development of new diagnostic tools,

  • understanding the development of tumors of the pancreas

  • the development of new therapeutic targets

  • understanding the response to chemotherapy...

Connect with a study center

  • Haut-Lévêque Hospital

    Bordeaux, 33604
    France

    Site Not Available

  • Béthune hospital center

    Béthune, 62408
    France

    Site Not Available

  • Huriez Hospital

    Lille, 59037
    France

    Site Not Available

  • Jean Mermoz private hosptila

    Lyon, 69008
    France

    Site Not Available

  • Regional Cancer Center From Montpellier

    Montpellier, 34298
    France

    Site Not Available

  • Saint Eloi Hospital

    Montpellier, 34295
    France

    Site Not Available

  • PAU hospital

    Pau, 6400
    France

    Site Not Available

  • Rangueil hospital

    Toulouse, 31059
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.